Get the Daily Brief
Latest Biotech News
NextCure Advances ADC Program with $745 Million Simcere Deal
NextCure has secured ex-China rights to Simcere Zaiming’s early-stage ADC candidate SIM0505 targeting CDH6 for up to $745 million. The antibody-drug conjugate combines a CDH6-targeted antibody...
CRISPR Patent Dispute Revived by US Appeals Court
A US appeals court has revived the patent dispute over CRISPR–Cas9 gene-editing technology between the University of California/University of Vienna team and the Broad Institute. The court found...
Nanoneedle Patch Enables Painless, Repeatable Tissue Diagnostics
Scientists at King’s College London have created a nanoneedle patch comprising millions of microscopic needles that collect molecular information from living tissues without pain or damage. This...
Breakthroughs in Cancer and Genetic Mutation Detection Tools
New computational algorithms are enhancing the detection of hidden protein variants resulting from complex genetic changes. UCLA and University of Toronto researchers developed moPepGen, a...
Roche and Prothena Proceed with Phase 3 Parkinson’s Trial Despite Mixed Results
Roche and Prothena are advancing prasinezumab, a Parkinson's disease antibody, into Phase 3 trials despite previous mid-stage studies missing primary endpoints. Analysts at Jefferies estimate only...
AI Applications Track Wildlife Behavior and Urban Ecological Impacts
Researchers at EPFL have launched MammAlps, a multi-view, multi-modal dataset capturing detailed wildlife behavior in the Swiss Alps, enabling sophisticated AI analysis to enhance conservation...
BioMérieux Bolsters Infectious Disease Diagnostics With Day Zero Acquisition
BioMérieux has expanded its next-generation sequencing (NGS) infectious disease testing capabilities through the acquisition of Day Zero Diagnostics' assets for approximately $25 million. Day...
Sage Therapeutics Acquired by Supernus for Up to $795 Million After Biogen Bid Rejection
Supernus Pharmaceuticals has agreed to acquire Sage Therapeutics for up to $795 million, including cash payments and contingent value rights tied to commercialization milestones. This acquisition...
Regeneron Steps Back as Anne Wojcicki Wins 23andMe Bankruptcy Bid
Regeneron Pharmaceuticals has lost the bankruptcy auction for 23andMe to former CEO Anne Wojcicki, whose nonprofit TTAM Research Institute submitted a $305 million bid exceeding Regeneron's $256...
Roche and Prothena Push Prasinezumab to Phase III Despite Mixed Phase IIb Results
Despite falling short in mid-stage trials, Roche and Prothena are advancing prasinezumab, a Parkinson’s disease monoclonal antibody, into Phase III testing. Analysts remain cautious, assigning a...
Nanoneedle Patch Developed at King’s College Offers Painless Alternative to Biopsies
Researchers at King's College London have created a nanoneedle patch equipped with millions of microscopic silicon needles thousands of times thinner than human hair, designed to collect molecular...
NextCure Invests $745M in Simcere’s Early-Stage ADC to Expand Oncology Pipeline
NextCure has inked a $745 million deal to secure ex-Greater China rights to Simcere Zaiming’s phase 1-stage antibody-drug conjugate (ADC) SIM0505, targeting CDH6. The ADC combines a targeted...
FDA Faces Delays and Resource Constraints Impacting Drug Approvals
The FDA is experiencing delays and potential consolidations within operational units such as human resources and communications to address workload challenges. Significant delays in drug...
Proteogenomics Tool ‘moPepGen’ Unveils Hidden Genetic Mutations at Protein Level
Scientists from UCLA and the University of Toronto have developed moPepGen, an innovative algorithm that enhances the detection of complex protein variants stemming from diverse genetic...
Sarepta Suspends Duchenne Gene Therapy Shipments Following Second Patient Death
Sarepta Therapeutics has temporarily halted Elevidys shipments for non-ambulatory Duchenne muscular dystrophy patients after a second death due to acute liver failure. Both fatalities involved...
Metabolic Drug DD01 Shows Promise in Reducing Liver Fat and Weight in MASH Patients
D&D Pharmatech reported positive phase 2 results for DD01, a dual GLP-1/glucagon receptor agonist, demonstrating significant reductions in liver fat—over 30% in 75.8% of treated patients—and...
Global warming worsens obstructive sleep apnea burden
New research published in Nature Communications reveals that rising global temperatures could increase the prevalence and severity of obstructive sleep apnea (OSA), a common yet underdiagnosed...
Nanoneedle patches promise pain-free cancer diagnostics
Scientists at King’s College London have unveiled a nanoneedle patch containing tens of millions of microscopic needles capable of sampling molecular data from tissues without pain or damage. This...
Massachusetts Governor Healey boosts biotech workforce with $1B investment
Massachusetts Governor Maura Healey has secured recognition as BIO’s 2025 Governor of the Year for spearheading a $1 billion state investment in life sciences through the Mass Leads Act. The...
Gilead and Arcellx report safer multiple myeloma CAR-T therapy
Gilead and Arcellx presented updated data indicating their cell therapy anito-cel for multiple myeloma maintains a favorable safety profile compared to competitors, while delivering comparable...